While inflation normalizes across the US economy, it continues to significantly influence the US Food and Drug Administration’s user fee programs.
Inflation Continues To Rear Head At US FDA User Fees
Inflation accounted for a larger portion of user fee revenue target increases for fiscal year 2025, compared to previous years, according to a Pink Sheet analysis.
